Protalix BioTherapeutics (PLX) Research & Development (2010 - 2026)
Protalix BioTherapeutics' quarterly Research & Development came in at $5.4 million in Q1 2026, up 56.14% year-on-year from $3.5 million in Q1 2025, and down 3.71% quarter-over-quarter from $5.6 million in Q4 2025.
Protalix BioTherapeutics has reported Research & Development for 17 years, with the latest figure at $5.4 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 56.14% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $21.5 million (up 58.73% YoY), and the FY2025 full-year result was $19.6 million, up 50.88% from the prior year.
- Research & Development for Q1 2026 stood at $5.4 million, down from $5.6 million in the prior quarter.
- The five-year high for Research & Development was $8.8 million in Q1 2022, with the low at $2.9 million in Q1 2024.
- Average Research & Development over 5 years is $5.0 million, with a median of $4.5 million recorded in 2023.
- Year-over-year, Research & Development plunged 50.62% in 2024 and jumped 102.36% in 2025.
- Tracing PLX's Research & Development over 5 years: stood at $5.6 million in 2022, then slumped by 44.77% to $3.1 million in 2023, then soared by 32.95% to $4.1 million in 2024, then surged by 36.64% to $5.6 million in 2025, then declined by 3.71% to $5.4 million in 2026.
- The last three Research & Development figures came in at $5.4 million (Q1 2026), $5.6 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 5.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.43 Mn |
| Dec 31, 2025 | 5.64 Mn |
| Sep 30, 2025 | 4.47 Mn |
| Jun 30, 2025 | 5.99 Mn |
| Mar 31, 2025 | 3.48 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Sep 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 2.96 Mn |
| Mar 31, 2024 | 2.89 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 3.67 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Mar 31, 2023 | 5.85 Mn |
| Dec 31, 2022 | 5.62 Mn |
| Sep 30, 2022 | 7.39 Mn |
| Jun 30, 2022 | 7.58 Mn |
| Mar 31, 2022 | 8.77 Mn |
| Dec 31, 2021 | 7.64 Mn |
| Sep 30, 2021 | 7.28 Mn |
| Jun 30, 2021 | 7.69 Mn |
| Mar 31, 2021 | 7.12 Mn |
| Dec 31, 2020 | 10.95 Mn |
| Sep 30, 2020 | 7.69 Mn |
| Jun 30, 2020 | 9.19 Mn |
| Mar 31, 2020 | 10.34 Mn |
| Dec 31, 2019 | 9.60 Mn |
| Sep 30, 2019 | 10.00 Mn |
| Jun 30, 2019 | 13.32 Mn |
| Mar 31, 2019 | 11.70 Mn |
| Dec 31, 2018 | 9.58 Mn |
| Sep 30, 2018 | 10.07 Mn |
| Jun 30, 2018 | 7.48 Mn |
| Mar 31, 2018 | 7.29 Mn |
| Dec 31, 2017 | 9.78 Mn |
| Sep 30, 2017 | 6.39 Mn |
| Jun 30, 2017 | 9.30 Mn |
| Mar 31, 2017 | 4.63 Mn |
| Dec 31, 2016 | 5.71 Mn |
| Sep 30, 2016 | 6.35 Mn |
| Jun 30, 2016 | 10.01 Mn |
| Mar 31, 2016 | 7.33 Mn |
| Dec 31, 2015 | 6.41 Mn |
| Sep 30, 2015 | 5.07 Mn |
| Jun 30, 2015 | 6.02 Mn |
| Mar 31, 2015 | 6.10 Mn |
| Mar 31, 2014 | 6.07 Mn |
| Dec 31, 2013 | 5.76 Mn |
| Sep 30, 2013 | 5.64 Mn |
| Jun 30, 2013 | 7.99 Mn |
| Mar 31, 2013 | 5.32 Mn |
| Dec 31, 2012 | 8.95 Mn |
| Sep 30, 2012 | 8.33 Mn |
| Jun 30, 2012 | 10.54 Mn |
| Mar 31, 2012 | 8.85 Mn |
| Dec 31, 2011 | 7.54 Mn |
| Sep 30, 2011 | 9.34 Mn |
| Jun 30, 2011 | 7.32 Mn |
| Mar 31, 2011 | 10.56 Mn |
| Dec 31, 2010 | 9.56 Mn |
| Sep 30, 2010 | 6.32 Mn |
| Jun 30, 2010 | 10.35 Mn |